Safety of ALK Ragweed Tablet

ALK-Abelló

Status and phase: Completed; Phase 1

Conditions: Allergy

Treatments: Biological: ALK Ragweed Tablet

Study type: Interventional

Funder types: Industry

Identifiers

NCT00330083

RT-01

Details and patient eligibility

About

This trial is performed to assess whether ALK Ragweed Tablet is safe to use in adults

Enrollment: 72 estimated patients

Sex: All

Ages: 18 to 50 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Ragweed pollen induced rhinoconjunctivitis
• Adults of either sex (18-50 years of age)
• Positive skin prick test to ragweed

Exclusion criteria

• Previous treatment with immunotherapy

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Double Blind